Getting to Zero San Francisco: A Collective Impact Approach.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
entrez:
26
11
2019
pubmed:
26
11
2019
medline:
6
6
2020
Statut:
ppublish
Résumé
Building on several decades of innovative HIV prevention and treatment programming in San Francisco, in 2014, a small group of academic, civic, and community leaders launched Getting to Zero San Francisco, a city-wide consortium focused on getting to zero HIV infections, zero HIV-related deaths, and zero HIV stigma and discrimination. San Francisco city and county. The consortium operates under the principles of collective impact composed of 5 components: a common agenda, shared measurement, mutually reinforcing activities, continuous communication, and organization backbone. Two flagship initiatives are described: citywide scale-up of pre-exposure prophylaxis and rapid antiretroviral therapy upon diagnosis. The number of new HIV diagnoses declined by over 50% from 399 to 197 from 2013 to 2018; the time from diagnosis to viral suppression decreased from 134 to 62 days during that period. However, continued racial/ethnic disparities in new HIV diagnoses and viral suppression rates point to the need for the Getting to Zero San Francisco committees to focus on racial/ethnic equity as a primary focus. Cisgender and transgender women, people who inject drugs, and people who are homeless also have lower viral suppression rates; ongoing initiatives are attempting to address these disparities. A collective impact implementation strategy that operates by unifying municipal organizations toward a common goal was associated with citywide gains in reducing new HIV diagnosis and time to viral suppression in San Francisco. Formal evaluation of this strategy will help elucidate under which conditions this approach is most likely to succeed.
Sections du résumé
BACKGROUND
Building on several decades of innovative HIV prevention and treatment programming in San Francisco, in 2014, a small group of academic, civic, and community leaders launched Getting to Zero San Francisco, a city-wide consortium focused on getting to zero HIV infections, zero HIV-related deaths, and zero HIV stigma and discrimination.
SETTING
San Francisco city and county.
METHODS
The consortium operates under the principles of collective impact composed of 5 components: a common agenda, shared measurement, mutually reinforcing activities, continuous communication, and organization backbone. Two flagship initiatives are described: citywide scale-up of pre-exposure prophylaxis and rapid antiretroviral therapy upon diagnosis.
RESULTS
The number of new HIV diagnoses declined by over 50% from 399 to 197 from 2013 to 2018; the time from diagnosis to viral suppression decreased from 134 to 62 days during that period. However, continued racial/ethnic disparities in new HIV diagnoses and viral suppression rates point to the need for the Getting to Zero San Francisco committees to focus on racial/ethnic equity as a primary focus. Cisgender and transgender women, people who inject drugs, and people who are homeless also have lower viral suppression rates; ongoing initiatives are attempting to address these disparities.
CONCLUSION
A collective impact implementation strategy that operates by unifying municipal organizations toward a common goal was associated with citywide gains in reducing new HIV diagnosis and time to viral suppression in San Francisco. Formal evaluation of this strategy will help elucidate under which conditions this approach is most likely to succeed.
Identifiants
pubmed: 31764252
doi: 10.1097/QAI.0000000000002200
pii: 00126334-201912003-00003
pmc: PMC6880800
mid: NIHMS1540376
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S176-S182Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI069496
Pays : United States
Références
J Acquir Immune Defic Syndr. 2019 May 1;81(1):57-62
pubmed: 30964805
Clin Infect Dis. 2018 Mar 19;66(7):1027-1034
pubmed: 29099913
Drug Alcohol Depend. 2018 Nov 1;192:125-128
pubmed: 30248558
J Am Pharm Assoc (2003). 2019 Aug 9;:null
pubmed: 31405804
JAMA. 2018 Jul 24;320(4):379-396
pubmed: 30043070
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):44-51
pubmed: 27434707
MMWR Morb Mortal Wkly Rep. 2019 Jul 12;68(27):597-603
pubmed: 31298662
JAMA. 2019 Mar 5;321(9):844-845
pubmed: 30730529
AIDS Care. 2019 Jul 17;:1-8
pubmed: 31315449
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):89-93
pubmed: 30272634
Lancet HIV. 2015 Jan;2(1):e1
pubmed: 26424230
AIDS. 2019 Apr 1;33(5):825-832
pubmed: 30882490
J Urban Health. 2017 Jun;94(3):350-363
pubmed: 28337575
JAMA Intern Med. 2019 Jun 11;:null
pubmed: 31184750
MMWR Morb Mortal Wkly Rep. 2018 Sep 21;67(37):1025-1031
pubmed: 30235184
Am J Epidemiol. 2011 Sep 1;174(5):515-22
pubmed: 21749972
AIDS Behav. 2019 Sep;23(9):2326-2336
pubmed: 31324996
MMWR Surveill Summ. 2014 Jul 4;63(6):1-51
pubmed: 24990587
Open Forum Infect Dis. 2019 Mar 27;6(5):ofz148
pubmed: 31139668
Am J Public Health. 2018 Nov;108(S4):S266-S273
pubmed: 30383430
J Int AIDS Soc. 2019 Apr;22(4):e25270
pubmed: 31037858
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):158-170
pubmed: 28628527
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
Am J Public Health. 2016 Oct;106(10):e2-3
pubmed: 27626355
Open Forum Infect Dis. 2018 Mar 14;5(3):ofy035
pubmed: 29577059